How to Buy Fulcrum Therapeutics Stock
Fulcrum Therapeutics Inc
Fulcrum Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States.
Fulcrum Therapeutics stock last closed at $6.83, up 1.49% from the previous day, and has decreased 24.2% in one year. It has overperformed other stocks in the Biotechnology industry by 0.42 percentage points. Fulcrum Therapeutics stock is currently +195.03% from its 52-week low of $2.32, and -32.58% from its 52-week high of $10.13.
At the moment, there are 54.09M shares of FULC outstanding. The market value of FULC is $369.45M. In the past 24 hours, 1.01M FULC shares were traded.
How to Buy Fulcrum Therapeutics Stock
Not sure how to invest in Fulcrum Therapeutics stock? Here's how.
- Decide where to buy Fulcrum Therapeutics stock: You need to choose an online brokerage, but don't worry - we've sifted through dozens of stock brokerages and apps to help you choose where to buy Fulcrum Therapeutics stock.
- Open a brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've found.
- Deposit funds into your investment account: Select your payment method and add your info.
- Research Fulcrum Therapeutics stock: The Fulcrum Therapeutics ticker symbol is FULC. Is Fulcrum Therapeutics stock a good investment? Should you buy shares of FULC? How do FULC's underlying business fundamentals look? Do top analysts think Fulcrum Therapeutics is a good buy? Why has FULC's stock price moved recently? (Hint: Our stock research tools can help you decide if FULC is a good stock to buy).
- Execute your FULC trade: Decide if you will purchase FULC shares at the current market price or use a limit order to purchase FULC stock at a particular price.
- Get updates on your FULC investment: Create a watchlist to key updates about your investment in Fulcrum Therapeutics shares.
Step 1: Decide where to buy Fulcrum Therapeutics stock
You will need a brokerage account to access the NASDAQ market and buy FULC shares.
Our preferred brokerage: eToro
Based on our research, eToro is the best stock brokerage. Here's why:
- Invest in stocks with 0% commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still buy the stock.
- Access to world financial markets: From Tech to Industrials, New York to Tokyo (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's top stock exchanges.
- Social investing: eToro has a community of more than 20 million users around the world. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your stock purchase by creating an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Open a brokerage account
Now that you've picked the right brokerage, you need to fill out some personal information so you are able to buy FULC today.
How to Start a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal info to open your new trading account.
- Submit your details by pressing the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your investment account
Now that you have filled out your info on the best stock app, you need to deposit funds:
Check out the video below if you need help depositing money into your new brokerage account.
Step 4: Research Fulcrum Therapeutics stock
After you have selected the best place to buy Fulcrum Therapeutics stock, it's absolutely critical to research their stock before you buy, so you actually wrap your head around the risk and opportunity.
Fulcrum Therapeutics Metrics
Fulcrum Therapeutics Fundamentals
WallStreetZen was created to help part-time investors do better fundamental analysis quickly.
You can view all of the due diligence checks on FULC's stock page.
Is FULC stock undervalued or overvalued?
Investors use a variety of different financial metrics, analyses, models, and charts to gauge FULC's fair value.
Using relative valuations ratios:
- FULC could be undervalued based on its P/B ratio of 1.72x, relative to Biotechnology industry P/B ratio of 4.3x
You can access more valuation analysis on FULC's stock here.
A look at FULC Cashflows and Balance Sheet
Passed Financial Due Diligence Checks:
- FULC has cash burn of 65225000. It has enough cash and short-term investments to cover this for at least one year.
- There are more short-term assets than short-term liabilities on the FULC balance sheet.
- FULC has $215.32M in cash and short term investments. This is sufficient to cover its annual cash burn of $65.23M.
- Total FULC debt is lower than 5 years ago, relative to shareholder equity.
- There are more short-term assets than long-term liabilities on the FULC balance sheet.
- FULC has a low debt to equity ratio of 0.07.
Is FULC stock a Buy, Hold, or Sell, according to Wall Street analysts?
Out of 5 Equities analysts who monitor FULC, the consensus analyst rating on Fulcrum Therapeutics is a Buy
Please note that analyst ratings are not recommendations, nor are they financial advice.
You can dig deeper into what analysts are forecasting on the Fulcrum Therapeutics stock forecast page.
Metrics for Advanced FULC Traders
FULC Earnings
Last year, FULC revenue was $0.00. Over the last 5 year, FULC's revenue has grown by -100% per year. This was slower than the Biotechnology industry average of 45.22%.
You can research FULC's earnings and revenue performance here.
Are FULC insiders buying or selling the stock?
Over the last year, executives and large shareholders at FULC have sold more shares than they have bought.
Greg Tourangeau, Principal Accounting Officer of FULC, was the latest FULC insider to sell. They sold $2,519.88 worth of FULC shares on May 8, 2025.
Research more about who owns FULC stock here.
Does FULC provide a stable income stream?
No, Fulcrum Therapeutics doesn't provide an income stream by paying out dividends.
Get analysis from other traders
One of the biggest reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to see what other community members have to say.
Step 5: Execute your FULC trade
You have two main order types:
- Market order: A market order is an order to buy or sell a stock at the best price on the market.
Market orders are mostly the best for newer investors. - Limit order: A limit order lets you buy or sell a security at a specific price (or better).
If you want to be sure you're buying or selling at a specific dollar amount, use a limit order.
Hit the Open Trade button and eToro will execute your order.
If you require additional help buying stocks on eToro, watch the helpful video below:
Step 6: Get updates on your FULC investment
Now that you own some FULC stock, you'll want to stay up-to-date on your new shares.
Put FULC on a watchlist to track the most important metrics related to your FULC stock.
FULC Feed
How to Buy Stock in Fulcrum Therapeutics
To summarize, here are the 6 steps to buy stock in Fulcrum Therapeutics:
- Decide where to buy Fulcrum Therapeutics stock
- Open a brokerage account
- Deposit funds into your investment account
- Research Fulcrum Therapeutics stock
- Execute your FULC trade
- Get updates on your FULC investment
If you need a place to buy stocks, eToro is our recommended option.
Get Started with eToro TodayIf you would like to keep an eye on your new investment in Fulcrum Therapeutics, get started below.
Other "How To" Guides You Might Enjoy
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.